Skip to content

Baseline Predictors of Response to Radial Pressure Wave Therapy in Knee Osteoarthritis

Baseline Predictors of Six-Month Clinical Response to Radial Pressure Wave Therapy in Patients With Knee Osteoarthritis: Secondary Analysis of a Randomized Double-Blind Clinical Trial.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07531160
Acronym
PRE-RPWT-OA
Enrollment
62
Registered
2026-04-15
Start date
2024-11-19
Completion date
2025-01-20
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis, Osteoarthritis, Knee

Keywords

Radial Pressure Wave Therapy, rESWT, Shockwave Therapy, Knee Osteoarthritis, Predictors, Clinical Response, Prognostic Factors

Brief summary

This observational study aims to identify baseline factors that predict clinical response at six months in patients with knee osteoarthritis treated with radial pressure wave therapy (rESWT). The study is a secondary analysis of data obtained from a randomized double-blind clinical trial conducted in 2024 at a tertiary care hospital in Mexico. Knee osteoarthritis is a common condition that causes pain, stiffness, and reduced physical function. Radial pressure wave therapy is a non-invasive treatment that has shown benefits in improving symptoms; however, not all patients respond equally. This study will analyze patient characteristics at baseline, such as age, body mass index, pain severity, and functional status, to determine which factors are associated with meaningful improvement in pain and function after treatment. The results may help clinicians better identify which patients are more likely to benefit from this therapy and improve personalized treatment decisions.

Detailed description

Background: Knee osteoarthritis (OA) is a leading cause of pain and disability worldwide. It is characterized by progressive joint degeneration, resulting in pain, stiffness, and functional limitations. Radial pressure wave therapy (rESWT) is a non-invasive treatment that has demonstrated effectiveness in reducing pain and improving function in patients with knee OA. However, there is significant variability in patient response, and the factors that predict treatment success are not well established. Objective: The aim of this study is to identify baseline predictors of clinical response at six months in patients with knee OA treated with rESWT. Methods: This study is a secondary analysis of a randomized double-blind clinical trial conducted in 2024 at the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde". The original trial evaluated the effectiveness of three standardized rESWT protocols in patients with knee OA. The present study is designed as an observational cohort analysis including patients with complete baseline and follow-up data. Baseline variables include demographic characteristics (age, sex), clinical factors (body mass index, baseline pain intensity, functional status), and radiographic severity. The primary outcome is the achievement of the minimal clinically important difference (MCID) in the WOMAC score at six months. Secondary outcomes include MCID in pain intensity measured by the Numerical Pain Rating Scale (NPRS) and changes in WOMAC and NPRS scores over time. Statistical analyses will be conducted to identify independent predictors of clinical response and to explore the interaction between baseline characteristics and treatment protocols. Significance: Identifying predictors of response to rESWT may improve patient selection, optimize treatment strategies, and contribute to more personalized and cost-effective care in patients with knee osteoarthritis.

Interventions

Radial pressure wave therapy (rESWT) administered according to standardized protocols in the original randomized clinical trial. The therapy involves the application of acoustic waves to the knee joint to reduce pain and improve function.

Sponsors

Hospital Civil de Guadalajara
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical and radiographic diagnosis of knee osteoarthritis * Participation in the original randomized double-blind clinical trial evaluating radial pressure wave therapy (rESWT) in 2024 * Availability of complete baseline data * Availability of follow-up data up to 6 months

Exclusion criteria

* Incomplete baseline or follow-up data * Withdrawal from the original trial before completion * Missing outcome measurements required for analysis * Presence of conditions that could interfere with outcome assessment or data validity

Design outcomes

Primary

MeasureTime frameDescription
Achievement of minimal clinically important difference (MCID) in pain intensity measured by the Numerical Pain Rating Scale (NPRS)6 months after baselineThe proportion of patients achieving the minimal clinically important difference (MCID) in pain intensity measured using the Numerical Pain Rating Scale (NPRS), a validated 0 to 10 scale where higher scores indicate greater pain.

Secondary

MeasureTime frameDescription
Achievement of minimal clinically important difference (MCID) in pain intensity measured by the Numerical Pain Rating Scale (NPRS)6 months after baselineThe proportion of patients achieving the minimal clinically important difference (MCID) in pain intensity measured using the Numerical Pain Rating Scale (NPRS), a validated 0 to 10 scale where higher scores indicate greater pain.
Change in WOMAC score over timeBaseline, 2 months, 4 months, and 6 monthsChange in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline across follow-up assessments, reflecting changes in pain, stiffness, and physical function.
Change in pain intensity measured by the Numerical Pain Rating Scale (NPRS) over timeBaseline, 2 months, 4 months, and 6 monthsChange in pain intensity from baseline measured using the Numerical Pain Rating Scale (NPRS) at different follow-up time points.

Countries

Mexico

Contacts

PRINCIPAL_INVESTIGATORArmando Tonatiuh Avila Garcia, MD

Hospital Civil de Guadalajara

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026